Connect Biopharma Hldgs (CNTB) closed at $0.73 on November 6, 2026, down 0.5% from the previous close, on volume of 321,407 shares (30-day average 6,868,324).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
Globe Newswire (Wed, 30-Sep 10:22 AM ET)
CNTB jumps after Phase 2 COPD trial reports 100% reduction in return ED/hospital visits at one month
Market Chameleon (Wed, 30-Sep 5:51 AM ET)
Globe Newswire (Wed, 30-Sep 7:00 AM ET)
Market Chameleon (Wed, 16-Sep 7:05 AM ET)
Globe Newswire (Tue, 15-Sep 7:00 AM ET)
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Connect Biopharma Hldgs trades on the NASDAQ stock market under the symbol CNTB.
As of November 6, 2026, CNTB stock price was flat at $0.73 with 321,407 million shares trading.
CNTB has a beta of -1.07, meaning it tends to be less sensitive to market movements. CNTB has a correlation of 0.02 to the broad based SPY ETF.
CNTB has a market cap of $45.88 million. This is considered a Sub-Micro Cap stock.
Last quarter Connect Biopharma Hldgs reported $3 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.04.
In the last 3 years, CNTB traded as high as $3.82 and as low as $.51.
The top ETF exchange traded funds that CNTB belongs to (by Net Assets): IWM, VTWO, IWO, IWN, IWC.
CNTB has underperformed the market in the last year with a price return of -56.1% while the SPY ETF gained +10.8%. CNTB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -66.7% and -4.9%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
CNTB support price is $.70 and resistance is $.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTB shares will trade within this expected range on the day.
